Biocytogen's Bispecific ADC Discovery Platform

Biocytogen has developed a bispecific ADC discovery platform using RenLite mice. Visit: biocytogen.com for more information

ABOUT THE PLATFORM
RenLite mice can generate fully human antibody backbones with common light chains. When combined with knobs-into-holes technology, the frequency of mismatch during bispecific antibody assembly is significantly reduced.
RenLite-derived bispecific ADCs have a simple monoclonal antibody structure and excellent physiochemical properties, including purity, stability, and an ideal DAR distribution, all of which facilitates the CMC process.
In combination with the advantages afforded by RenLite-based bispecific antibody discovery, Biocytogen’s established in vitro and in vivo pharmacologic efficacy platforms allow for large-scale screening to uncover novel bispecific antibody and bispecific ADC therapeutic candidates that are suitable for clinical development.
Over the past 2 years, we’ve already identified over 20 preclinical candidates and more than 40 TAA-targeting monoclonal antibody back bone hits ready for bispecific antibody and bispecific ADC assembly.